Description
ECI830 is an experimental medication currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being investigated as a single agent (given alone) or in combination with other drugs like ribociclib and fulvestrant. The trials are in early phases (Phase 1), meaning they are primarily focused on determining the safety and appropriate dosage of ECI830. Some trials specifically include patients whose tumors have certain characteristics, such as CCNE1 amplification or HER2 mutations. ECI830 is being developed by Novartis Pharmaceuticals. It is not yet approved for use in colorectal cancer or any other condition.
Mechanism of Action
ECI830 is being studied as a potential treatment for cancers that have specific genetic changes. The specific way ECI830 works at a molecular level (its target) is still being investigated in clinical trials. It is designed to target proteins involved in tumor growth and survival, potentially interfering with the processes that allow cancer cells to multiply and spread. The trials are evaluating its effects on tumor cells and overall patient response.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.